| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Kronos Bio Reels In $105M for Drugs That Hit “Undruggable” Targets | Frank Vinluan | 07/18/19 | San Francisco |
| Roche Vet O’Day Tapped to Shape Gilead’s Future as Hep C Sales Fall | Ben Fidler | 12/10/18 | San Francisco |
| Bio Roundup: Brii Does China, Hemophilia Updates, Right to Try & More | Ben Fidler | 05/25/18 | National |
| Nimbus’s LLC Origins Pay off As Gilead Shells Out $400M For Liver Drug | Ben Fidler | 04/04/16 | Boston |
| West Coast Biotech Roundup: Halozyme, Nektar, Allozyne, Novo & More | Alex Lash | 09/18/14 | Seattle |
| Biotech and Fantasy Football Picks for Fall 2013 | Luke Timmerman | 09/03/13 | National |
| Gilead Wagers $600M on Calistoga, Dendreon Scopes New Digs, Physio to Spin Off, & More Seattle-Area Life Sciences News | Luke Timmerman | 02/24/11 | Seattle |
| Gilead Pursues Cancer, Inflammation as Next Step To Diversify Beyond HIV | Luke Timmerman | 02/23/11 | San Francisco |
| Calistoga Hands the Keys to Gilead, Bets It Can Make Cancer a Chronic Disease Like HIV | Luke Timmerman | 02/23/11 | Seattle |
| Gilead Buys Calistoga Pharma for $375M, Making Move Into Cancer Drugs | Luke Timmerman | 02/22/11 | Seattle |
| Gilead Cystic Fibrosis Drug Gets Green Light From FDA Panel | Luke Timmerman | 12/10/09 | Seattle |
